
This is the author’s final accepted version.

There may be differences between this version and the published version. You are advised to consult the publisher’s version if you wish to cite from it.

[http://eprints.gla.ac.uk/148735/](http://eprints.gla.ac.uk/148735/)

Deposited on: 26 September 2017

Enlighten – Research publications by members of the University of Glasgow
[http://eprints.gla.ac.uk](http://eprints.gla.ac.uk)
Beating type 2 diabetes into remission

Louise McCombie, researcher1 [Q to A Please give one job title for each author, eg researcher, professor, consultant] Wilma Leslie, researcher2 Roy Taylor, professor2, Brian Kennon, consultant3 Naveed Sattar, professor4, Mike E J Lean, professor1

1 Human Nutrition Section, School of Medicine, University of Glasgow, Glasgow, G31 2ER, UK
2 Magnetic Resonance Centre, Campus for Ageing and Vitality, University of Newcastle, Newcastle Upon Tyne, UK
3 Diabetes Centre, Queen Elizabeth University Hospital, Glasgow
4 University of Glasgow Biomedical Research Centre, Glasgow

Correspondence to: L McCombie louise.mccombie@glasgow.ac.uk

Recognising and accurately coding reversal of type 2 diabetes is key to improving outcomes and reducing healthcare costs, argue Louise McCombie and colleagues

Type 2 diabetes, generally perceived as progressive and incurable, now affects 5-10% of the population, about 3.2 million people in the UK. Until complications develop, most patients are managed entirely within primary care, with diabetes comprising a major part of general practice activity. About 10% of total UK NHS expenditure goes on treating diabetes, and international figures suggest that medical costs with diabetes are 2-3 fold greater than the average for age- and sex-matched people without diabetes. Application of current clinical guidelines to reduce glycated haemoglobin (HbA1c) levels and cardiovascular risks, primarily with drugs and generic lifestyle advice, has improved clinical outcomes, but many patients still develop vascular complications, and life expectancy remains up to six years shorter than in people without diabetes. The diagnosis carries important social and financial penalties for individuals, as well as poor health prospects.

Remission of diabetes (no longer having diabetes, at least for a period) is clearly attainable for some, possibly many, patients but is currently very rarely achieved or recorded. Greater awareness, documentation, and surveillance of remissions should improve health outcomes and reduce healthcare costs.
Changing management

In keeping with trends in most medical specialties, diabetes management is beginning to focus on reversible underlying disease mechanisms rather than treating symptoms and subsequent multisystem pathological consequences. Both (epi)genetic predisposition and ageing have a role in type 2 diabetes, but it is rare without weight gain.

Lowering blood glucose or HbA1c concentrations remains the primary aim of management, as reflected in current clinical guidelines and the actions of licensed drugs. However, management and guidelines focus strongly on use of antidiabetes drugs, with only lip service paid to diet and lifestyle advice. The scale of the market for drug therapies, and their likely inadequacy, is illustrated by the fact that 488 drugs (excluding insulins) are currently licensed worldwide to treat type 2 diabetes, with 70 generic compounds. They all lower blood glucose and HbA1c significantly, but no trials have yet examined drugs administered together with optimal diet and lifestyle advice for weight control.

In contrast, consistent evidence shows that weight loss is associated with extended life expectancy for people with diabetes, and that weight loss of around 15kg often produces total biochemical remission of type 2 diabetes, restoring beta cell function and. Recognition that accumulation of ectopic fat in the liver and pancreas impairs organ function cause type 2 diabetes, but is reversible, has raised awareness that remission is possible. Media attention has encouraged increasing numbers of people with type 2 diabetes to lose weight and shed the diagnosis. Remission produces a strong sense of personal achievement and empowerment, and also benefits medical systems because patients no longer require antidiabetes drugs. The UK NHS currently spends almost £1bn (€1bn; $1.3bn) a year (£22m a day) on antidiabetes drugs, and costs are rising worldwide as diabetes rates and drug prices escalate.

Criteria for remission of diabetes

There is no final consensus on the criteria for declaring a remission of diabetes. The published criteria, and thus reported remission rates, vary, but all require being below the World Health Organization/American Diabetes Association (ADA) diagnostic thresholds for diabetes (table 1). Most recent publications, including the Look AHEAD trial, refer to an ADA consensus group statement that defined test results below the diagnostic
threshold for diabetes as partial remission and remission of “pre-diabetes” as complete remission.

However, using the term partial remission does not fully portray the logic or importance of becoming non-diabetic to patients. Although remission of prediabetes is desirable because it reduces cardiovascular risk, routine management should aim to help patients escape the diagnostic category of diabetes, with its personal burdens and risks of microvascular disease. That requires using the WHO diagnostic thresholds for diabetes to establish remission and accepting that some patients will continue to have impaired glucose tolerance or prediabetic fasting glucose and HbA1c profiles. Measurement of either HbA1c or blood glucose is sufficient to identify remission. To avoid misclassification resulting from measurement error or biological variation, patients should have two tests results (usually HbA1c) below the diagnostic threshold, at least two months apart to confirm remission. This reflects about four months of normoglycaemia. Patients in remission should be kept under regular review with annual testing (table 1).

**Potential metabolic value of remission**

Clinical outcomes for people with type 2 diabetes are all worse at higher glucose or HbA1c concentrations. No study has yet reported outcomes for people who achieve remission, but good glycaemic control through drug treatment improves microvascular outcomes (retinopathy, neuropathy, nephropathy) in both type 1 and type 2 diabetes. Reduced cardiac events have also been observed in patients with type 2 diabetes after bariatric surgery. In contrast, some drug trials have indicated increased mortality when HbA1c approaches normal levels, probably through hypoglycaemia provoking arrhythmias. Look AHEAD, a trial of lifestyle intervention in patients with mean diabetes duration of five years, reported 11.5% remission at 12 months with 8.6% weight loss, but that proportion fell by about 30% annually. Health outcomes of participants have not yet been reported, but the limited evidence and first principles suggest that remission of diabetes (without antidiabetes drugs) should enhance overall prognosis, becoming a primary management target as early as possible after diagnosis.

**Coding for health records**

Remission of type 2 diabetes can be inferred from routine records of patients labelled diabetic who have non-diabetic biochemical test results (usually HbA1c<48 mmol/mol), when
there is no record that antidiabetes drugs are prescribed. In the UK, clinicians have used Read codes to record patients’ findings and procedures since 1985 but are now converting to the international SNOMED system. The basic coding framework will remain, however.

The Read code dictionary includes codes 21263 or 212H for “diabetes resolved” and C10P for “diabetes in remission.” Diabetes resolved is used for patients misdiagnosed with diabetes or in whom diabetes was secondary to a factor that has since been removed, such as withdrawal of steroid treatment. Such patients do not require annual reviews or surveillance. Code C10P should be used for patients who have achieved remission of type 2 diabetes, usually by substantial weight loss. These patients may be considered non-diabetic for matters such as insurance, driving, or employment but as the code is diagnostic they will remain scheduled for annual reviews and retinal screening programmes.

**Achieving remission**

In the few countries with data, patients are seldom recorded as having diabetes in remission. Karter and colleagues found remissions in only 0.14% of 120 000 US patients followed for seven years. The Scottish Care Information Diabetes database, which includes every patient in Scotland, shows that less than 0.1% of those with type 2 diabetes (245/254 208) were coded as being in remission in March 2017 (table 2). Lack of agreed criteria and guidance over recoding may have led to hesitation in coding remission, but the main reason for the low recording is probably that few patients are attempting or achieving remission. Patients and doctors may be unaware that type 2 diabetes can be reversed, despite recent publicity. The feasibility of sustained substantial intentional dietary weight loss is widely doubted, despite publications of structured approaches using an initial formula diet replacement to achieve rapid substantial weight loss and then maintain 12-15 kg loss at 12 months and beyond.

The 2010 guideline of the Scottish Intercollegiate Guidelines Network recommends sustained weight loss above 10% of body weight or 15 kg for people with severe and complicated obesity, including type 2 diabetes. This is difficult to achieve, even with bariatric surgery, and only 75-80% of patients who succeed are rewarded with diabetes remission.
The drivers and barriers to successful remission are not fully evaluated but are likely to include age, body mass index, duration of diabetes, HbA1c concentrations, and drug treatment. Physical and social environments, emotional states, and self regulatory skills are important factors affecting adherence to a weight management intervention. It is unknown whether the degree of weight loss needed to achieve remission will be the same for Asian people, who commonly develop type 2 diabetes at a lower body mass index than people of European origin, but probably with similar body fat content.

Doctors may be understandably reluctant to redefine a patient as “in remission” if they are concerned that the remission, dependent on maintaining weight loss, may not persist, and that routine recall for annual checks might cease. However, under the remission coding annual reviews and screening recalls will continue. Another UK specific factor may have been fear of losing the incentive payments for managing diabetes under the Quality and Outcomes Framework (QOF). Again, coding “diabetes in remission” retains the diagnostic status so the practice payment would continue.

Diabetes in remission has not been specifically rewarded as a management target in QOF. Incentives have been shown to improve care and risk factors in other areas such as asthma and cardiovascular disease. Forthcoming revisions of QOF in NHS England, and its replacement in NHS Scotland, provide opportunities to include diabetes remission as an incentivised target.

**Benefits of remission**

Achieving remission has health benefits for patients and removes the burden of daily monitoring and treatment, but correct coding of remission has multiple further benefits. It removes the stigma of having diabetes and provides a sense of personal achievement and social status (Box 1).

**Box 1: Benefits of coding remission of diabetes**

**For patients**
- Removes personal and social stigmatisation as diseased or “diabetic”
- Provides a target and a reward for the sustained hard work usually necessary to achieve and maintain substantial weight loss
- May permit life insurance, mortgages, travel insurance, etc without the higher premiums added for people with a diagnosis of type 2 diabetes
- Removes some occupational restrictions

**For epidemiology and health systems**
• Identifies a valuable indicator of success in healthcare, through national disease register monitoring
• Allows better analysis of long term morbidity and mortality risks
• Improves resource requirement forecasting

Diabetes is expensive, both for individuals and for health systems. Evidence is needed on health demands and survival after remission, but the demands are likely to be lower. The average annual medical costs of type 2 diabetes in the US were calculated at $6414 (£5000; €5400) in 2007, rising with age to $9061 aged over 64, around 2.5 times greater than for people without diabetes.\textsuperscript{20}

The costs are climbing as expensive new drugs are launched, under pharmacocentric clinical guidelines. In UK these rising costs are borne by the NHS. In other countries, costs fall to the individual. Private health insurance will not usually cover existing diabetes, presenting a barrier to optimal medical care. Thus significantly more US adults with diabetes, and the majority aged over 65, rely on public insurance such as Medicare. The American Diabetes Association provides indicative costs of Medicare cover for people with diabetes. Annual premiums are around $1200 plus (optionally) $166 to allow about half of prescription drug costs to be covered. Prescription costs are not full covered until an individual has spent over $4950 on drugs in a year.\textsuperscript{22} The 2009 US National Health Interview Survey found that, depending on total household income, people aged 18-64 with diabetes spend about $3000 a year on private health insurance premiums, or $2000-$6000 a year on healthcare (of poorer quality) if they do not have health insurance.\textsuperscript{23}

Other types of insurance are also more expensive. Life assurance premiums are commonly doubled for people with diabetes, adding around £600 a year to an average policy. The international online insurance broker moneysupermarket.com currently offers people with type 2 diabetes equivalent travel policies at almost double the price of that for a person without medical problems, adding £20-£30 to the cost of 14 days cover in the US, or more if insulin is needed. At present, people who have diabetes in remission are included in the cheaper category (as are people with prediabetes). Awareness of tangible cost savings of this kind might help maintain weight loss and remission of type 2 diabetes: the promise of rewards and praise for goals achieved are key elements in behaviour change strategy.

\textbf{Moving forward}
It is in everybody’s interest to reclassify people with type 2 diabetes when they become non-diabetic. Official guidelines and international consensus for recording diabetes in remission are needed. We have proposed that two non-diabetic test results, at least two months apart, should be required, with annual reviews of HbA1c, to confirm continuation (table 1). The appropriate interval between tests for establishing remission is open to debate. It must be long enough to eliminate people with temporary dips in glycaemia but short enough for patients to maintain motivation. Having agreed criteria for coding diabetes in remission (C10P in UK) in record systems will benefit patients and healthcare planning. Appropriate coding will make it possible to monitor progress in achieving remission of type 2 diabetes nationally and internationally and to improve predictions of long term health outcomes for patients with a known duration of remission.

**Key messages**

Remission of type 2 diabetes is achievable through substantial weight loss but is rarely recorded and probably under-reported
Recognising remission of diabetes can be a powerful motivator for patients to maintain weight loss
Diagnostic coding of “diabetes in remission” alleviates the social and financial penalties of diagnosis for patients while continuing medical surveillance
Correct coding provides a valuable indication of healthcare success and can inform healthcare planning

Contributors and sources: LMcC and MEJL conceived of the original idea. LMcC, MEJL, RT, NS, and WL all have experience and expertise in weight management and are involved in the Diabetes UK funded Diabetes Remission Clinical Trial. BK provided data on current diabetes recording. LMcC wrote the first draft. All authors contributed to and revised the manuscript. MEJL is the guarantor.

Competing interests: We have read and understand BMJ policy on declarations of interest and declare that with the exception of BK all authors are involved in the Diabetes UK funded Diabetes Remission Clinical Trial. LMcC and MEJL provide consultancy to Counterweight Ltd.

Provenance and peer review: Not commissioned; externally peer reviewed.


<unknown>5 Medtrik. Anti-diabetes medications in US and Europe, April 2017 [Q to A Is there a url for this?](unknown>

</p>


</jrn>


</jrn>


</jrn>


</jrn>


</jrn>


</jrn>


</jrn>


</jrn>


</jrn>


</unknown>


</jrn>


</jrn>
Criteria for remission

<table>
<thead>
<tr>
<th>ADA Consensus Group</th>
</tr>
</thead>
</table>

Confirmation

<table>
<thead>
<tr>
<th>Partial remission (no longer having diabetes): Both HbA1c &lt; 6.5% (&lt;48 mmol/mol) and fasting blood glucose 5.6-6.9 mmol/L without antidiabetes drugs (time not specified)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Maintained for 1 year</td>
</tr>
<tr>
<td>Complete remission (no longer having prediabetes): Both HbA1c &lt; 6% (&lt;42 mmol/mol) and fasting blood glucose &lt;5.6 mmol/L without antidiabetes drugs (time not specified)</td>
</tr>
<tr>
<td>Maintained for 1 year</td>
</tr>
<tr>
<td>HbA1c &lt; 6% (42 mmol/mol) or fasting blood glucose &lt;5.6 mmol/L without antidiabetic drugs (time not specified)</td>
</tr>
<tr>
<td>None</td>
</tr>
<tr>
<td>Previous diagnosis of type 2 diabetes by WHO criteria. HbA1c &lt; 6.5% (&lt;48 mmol/mol) or fasting blood glucose &lt;7 mmol/L and 2 hour glucose &lt;11 mmol/L after at least 2 months without antidiabetes medication</td>
</tr>
<tr>
<td>Two non-diabetic test results, at least 2 months apart then reviewed annually</td>
</tr>
</tbody>
</table>

Table 2 Numbers of people in Scotland with different coding categories registered in the SCI Diabetes database (March 2017)

<table>
<thead>
<tr>
<th>Diabetes category</th>
<th>No of patients</th>
</tr>
</thead>
<tbody>
<tr>
<td>DD-DMT-01 Type 1 diabetes mellitus</td>
<td>30 568</td>
</tr>
<tr>
<td>DD-DMT-02 Type 2 diabetes mellitus</td>
<td>254 208</td>
</tr>
<tr>
<td>DD-DMT-03 Current gestational diabetes</td>
<td>20</td>
</tr>
<tr>
<td>DD-DMT-04 Maturity onset diabetes of youth</td>
<td>212</td>
</tr>
<tr>
<td>DD-DMT-05 Latent autoimmune diabetes of adulthood</td>
<td>196</td>
</tr>
<tr>
<td>DD-DMT-06 Maternally inherited diabetes and deafness</td>
<td>12</td>
</tr>
</tbody>
</table>